NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 October 2011 The published data from ROCKET AF in 14,264 patients with nonvalvular atrial fibrillation (AF), who were at moderate to high risk of stroke, found that rivaroxaban […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 11 October 2011 The REALIZE trial (n = 663) found that the addition of oral telaprevir▼to standard therapy with peginterferon alfa-ribavirin was significantly more effective than standard treatment alone […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 13 September 2011 The ADVANCE trial (n = 1,095) found that in previously untreated patients with genotype 1 hepatitis C infection and a baseline hepatitis C virus RNA level […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 2 September 2011 A once-weekly exenatide 2mg suspension for subcutaneous injection (Bydureon ▼®) has recently been launched for the management of type 2 diabetes. This prolonged- release formulation is […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 2 August 2011 The HCV RESPOND-2 trial (n=404) found that oral boceprevir given three times a day in addition to peginterferon alfa and ribavirin significantly increased rates of sustained […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 14 July 2011 The SPRINT-2 trial (n=1,097) found that oral boceprevir given three times a day, plus standard therapy of peginterferon alfa-ribavirin, significantly increased rates of sustained virologic response […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 17 May 2011 The Bribery Act 2010 comes into force on 1st July 2011. This aims to tackle bribery and corruption in both the public and private sector. NHS […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 21 April 2011 According to a press release, results from the DURATION-6 study show that once weekly exenatide 2mg s.c. did not achieve the primary endpoint of non-inferiority  to […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 20 April 2011 In ADVANCE-3 (n=5,407), oral apixaban 2.5mg twice daily was associated with lower rates of a composite endpoint of both disease and patient-oriented outcomes than subcutaneous enoxaparin […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 14th February 2011 Two phase III EINSTEIN trials of rivaroxaban▼ (Xarelto®) have recently been published as a single paper. The EINSTEIN–DVT (Acute) Study (n=3,449) found that rivaroxaban was non-inferior […]